ERT acquires invivodata

Monday, July 9, 2012 01:38 PM

ERT, a global technology-driven provider of health outcomes services, has decided to acquire invivodata, a provider of electronic Patient Reported Outcomes (ePRO) solutions and consulting services, based in Pittsburgh, Penn.

The transaction was facilitated by the San Francisco-based private equity group, Genstar Capital, which last week completed its acquisition of ERT. The invivodata acquisition immediately positions ERT as a leader in clinical outcome assessments (COA). The combined organization will now offer sponsors, CROs and other third-party vendors a combination of market-leading electronic patient reported outcomes (ePRO)/COA solutions and scientific and regulatory consulting services that is unrivalled in the industry.

The invivodata consulting group bolsters ERT’s position in health outcomes research and complements its market leading position in cardiac safety and respiratory outcomes assessment. The acquisition also enhances ERT’s multi-mode ePRO product portfolio with the introduction of a suite of proven site-based and patient-friendly handheld devices that have already been validated to collect therapy-specific diaries, instruments and assessments.

“For some time, ERT has been working in collaboration with sponsors and partners to establish a new model of delivering value through the centralization of health outcomes data,” said Jeffrey Litwin, CEO of ERT. “By adding invivodata’s team of scientists and technology experts, we accelerated this strategic initiative, which will provide our joint clients with consistent, scientifically accurate outcome assessment data which will be accessible from one platform.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs